11β-alkyl-Δ9-19-nortestosterone derivatives: High-affinity ligands and potent partial agonists of the androgen receptor

Journal of Medicinal Chemistry

Volumn 47, Issue 21, 2004, Pages 4985-4988

  Muddana, Smita S ^a   Price, Aimee M ^a   MacBride, Megan M ^a   Peterson, Blake R ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; ANTIGESTAGEN; CYPROTERONE ACETATE; GLUCOCORTICOID ANTAGONIST; MIFEPRISTONE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NANDROLONE DERIVATIVE; PARTIAL AGONIST; RECOMBINANT PROTEIN; TESTOSTERONE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; LIGAND; NANDROLONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DIMERIZATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; LIGAND BINDING; MALE; PROSTATE CANCER; RECEPTOR AFFINITY; ANIMAL; CHEMISTRY; CHO CELL; DRUG ANTAGONISM; DRUG POTENTIATION; HAMSTER; PROSTATE TUMOR; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CYPROTERONE ACETATE; DIMERIZATION; HUMANS; LIGANDS; MALE; MIFEPRISTONE; NANDROLONE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4744346088     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0342515     Document Type: Article

References (36)

1. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; et al. The nuclear receptor superfamily: the second decade. Cell 1985, 83, 835-839.
2. Gottlieb, B.; Lehvaslaiho, H.; Beitel, L. K; Lumbroso, R.; Pinsky, L.; et al. The Androgen Receptor Gene Mutations Database. Nucl. Acids Res. 1998, 26, 234-238.
3. Yong, E. L.; Tut, T. G.; Ghadessy, F. J.; Prins, G.; Ratnam, S. S. Partial Androgen Insensitivity and Correlations with the Predicted Three-Dimensional Structure of the Androgen Receptor Ligand-Binding Domain. Mol. Cell. Biol. 1998, 137, 41-50.
4. Matias, P. M.; Donner, P.; Coelho, R.; Thomaz, M.; Peixoto, C.; et al. Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor. J. Biol. Chem. 2000, 275, 26164-26171.
5. Langley, E.; Kemppainen, J. A.; Wilson, E. M. Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J. Biol. Chem. 1998, 273, 92-101.
6. Snyder, P. J. Androgens. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed.; McGraw-Hill: New York, 2001; pp 1635-1648.
7. Gaddipati, J. P.; McLeod, D. G.; Heidenberg, H. B.; Sesterhenn, I. A.; Finger, M. J.; et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 1994, 54, 2861-2864.
8. Kuil, C. W.; Mulder, E. Mechanism of Antiandrogen Action: Conformational Changes of the Receptor. Mol. Cell. Endocrinol. 1994, 102, R1-R5.
9. Lin, M. F.; Kawachi, M. H.; Stallcup, M. R.; Grunberg, S. M.; Lin, F. F. Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 1995, 26, 194-204.
10. El Etreby, M. F.; Liang, Y.; Johnson, M. H.; Lewis, R. W. Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate 2000, 42, 99-106.
11. Liang, Y.; Eid, M. A.; El Etreby, F.; Lewis, R. W.; Kumar, M. V. Mifepristone-induced secretion of transforming growth factor betal-induced apoptosis in prostate cancer cells. Int. J. Oncol. 2002, 21, 1259-1267.
12. Song, L. N.; Coghlan, M.; Gelmann, E. P. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol. Endocrinol. 2004, 18, 70-85.
13. Fuhrmann, U.; Hess-Stumpp, H.; Cleve, A.; Neef, G.; Schwede, W.; et al. Synthesis and Biological Activity of a Novel, Highly Potent Progesterone Receptor Antagonist. J. Med. Chem. 2000, 43, 5010-5016.
14. Kauppi, B.; Jakob, C.; Farnegardh, M.; Yang, J.; Ahola, H.; et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. 2003, 278, 22748-22754.
15. Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-758.
16. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95, 927-937.
17. Pike, A. C.; Brzozowski, A. M.; Walton, J.; Hubbard, R. E.; Thorsell, A.; et al. Structural Insights into the Mode of Action of a Pure Antiestrogen. Structure 2001, 9, 145-153.
18. Honer, C.; Nam, K.; Fink, C.; Marshall, P.; Ksander, G.; et al. Glucocorticoid receptor antagonism by cyproterone acetate and RU486. Mol. Pharmacol. 2003, 63, 1012-1020.
19. Wakeling, A. E.; Bowler, J. ICI 182,780, a new antiestrogen with clinical potential. J. Steroid Biochem. Mol. Biol. 1982, 43, 173-177.
20. Sack, J. S.; Kish, K. F.; Wang, C.; Attar, R. M.; Kiefer, S. E.; et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4904-4909.
21. Matias, P. M.; Carrondo, M. A.; Coelho, R.; Thomaz, M.; Zhao, X. Y.; et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J. Med. Chem. 2002, 45, 1439-1446.
22. Holland, H. L.; Taylor, G. J. Enzymic Aromatization of Deuterium Labelled Testosterone and Androst-4-ene-3,17-dione. Can. J. Chem. 1981, 59, 2809-2819.
23. Ottow, E.; Beier, S.; Elger, W.; Henderson, D. A.; Neef, G.; et al. Synthesis of Ent-17-(prop-1-ynyl-17β-hydroxy-11β-(4-N,N-dimethylamino) -phenyl)-4,9-estradien-3-one, the Antipode of RU-38 486. Steroids 1984, 44, 519-530.
24. Ponsold, K. Synthese von 3-Keto-4,9-diensteroiden mit polymeren Reagenzien. Z. Chem. 1986, 26, 371.
25. 4,9-3-Ketosteroids. J. Am. Chem. Soc. 1960, 82, 2402-2403.
26. Faraj, H.; Claire, M.; Rondot, A.; Aumelas, A.; Auzou, G. Synthesis of New Steroidal 11β-Substituted Spirolactones. J. Chem. Soc., Perkin Trans. 1 1990, 3045-3048.
27. Napolitano, E.; Fiaschi, R.; Hanson, R. N. Epoxidation of Estra-5 (10), 9 (11)-diene Derivatives; A Convenient Synthesis of 11β-Vinylestrone Acetate. Gazz. Chim. Ital. 1990, 120, 323-326.
28. Teutsch, G.; Belanger, A.; Philibert, D.; Tournemine, C. Synthesis of 11β-Vinyl-19-norsteroids as Potent Progestins. Steroids 1982, 39, 607-615.
29. Belanger, A.; Philibert, D.; Teutsch, G. Regio and Stereospecific Synthesis of 11β-Substituted 19-Norsteroids: Influence of 11β-Substitution on Progesterone Receptor Affinity. Steroids 1981, 37, 361-382.
30. He, B.; Kemppainen, J. A.; Wilson, E. M. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 2000, 275, 22986-22994.
31. Langley, E.; Zhou, Z.; Wilson, E. M. Evidence for an Antiparallel Orientation of the Ligand-activated Human Androgen Receptor Dimer. J. Biol. Chem. 1985, 270, 29983-29990.
32. Danielsen, M.; Northrop, J. P.; Ringold, G. M. The mouse glucocorticoid receptor: mapping of functional domains by cloning, sequencing and expression of wild-type and mutant receptor proteins. EMBO J. 1986, 5, 2513-2522.
33. Nordeen, S. K. Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques 1988, 6, 454-458.
34. Veldscholte, J.; Ris-Stalpers, C.; Kuiper, G. G.; Jenster, G.; Berrevoets, C.; et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 1990, 173, 534-540.
35. Kuil, C. W.; Mulder, E. Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: implications for the actions of androgens and antiandrogens. Endocrinology 1998, 137, 1870-1877.
36. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.